Atrion Co. (NASDAQ:ATRI) has received an average broker rating score of 5.00 (Strong Sell) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.
Zacks has also assigned Atrion an industry rank of 221 out of 265 based on the ratings given to its competitors.
Separately, BidaskClub downgraded Atrion from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th.
Atrion (NASDAQ ATRI) traded down $3.00 during trading hours on Monday, reaching $600.50. 9,612 shares of the company were exchanged, compared to its average volume of 6,431. Atrion has a 1 year low of $459.05 and a 1 year high of $694.00. The stock has a market cap of $1,110.00, a price-to-earnings ratio of 33.64 and a beta of 0.70.
Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. Atrion had a net margin of 24.96% and a return on equity of 19.53%. The firm had revenue of $34.02 million for the quarter.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Thursday, March 15th will be issued a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 14th. Atrion’s dividend payout ratio (DPR) is currently 26.89%.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/zacks-atrion-co-atri-receives-average-rating-of-strong-sell-from-analysts.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.